Cargando…

Galectin-3 as a Predictor of Left Ventricular Reverse Remodeling in Recent-Onset Dilated Cardiomyopathy

OBJECTIVES: Studies have evaluated the association of galectin-3 and outcome in patients with heart failure. However, there is still scarce evidence concerning the clinical usefulness and predictive value of galectin-3 for left ventricular reverse remodeling (LVRR) in patients with recent-onset dila...

Descripción completa

Detalles Bibliográficos
Autores principales: Karatolios, Konstantinos, Chatzis, Georgios, Holzendorf, Volker, Störk, Stefan, Richter, Anette, Binas, Davis, Schieffer, Bernhard, Pankuweit, Sabine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029471/
https://www.ncbi.nlm.nih.gov/pubmed/30018673
http://dx.doi.org/10.1155/2018/2958219
_version_ 1783336969226420224
author Karatolios, Konstantinos
Chatzis, Georgios
Holzendorf, Volker
Störk, Stefan
Richter, Anette
Binas, Davis
Schieffer, Bernhard
Pankuweit, Sabine
author_facet Karatolios, Konstantinos
Chatzis, Georgios
Holzendorf, Volker
Störk, Stefan
Richter, Anette
Binas, Davis
Schieffer, Bernhard
Pankuweit, Sabine
author_sort Karatolios, Konstantinos
collection PubMed
description OBJECTIVES: Studies have evaluated the association of galectin-3 and outcome in patients with heart failure. However, there is still scarce evidence concerning the clinical usefulness and predictive value of galectin-3 for left ventricular reverse remodeling (LVRR) in patients with recent-onset dilated cardiomyopathy (RODCM). PATIENTS AND METHODS: Baseline galectin-3 was measured in 57 patients with RODCM. All patients were followed for at least 12 months. The study end point was LVRR at 12 months, defined as an absolute improvement of the left ventricular ejection fraction of ≥10% to a final value of ≥35%, accompanied by a decrease in the left ventricular end diastolic diameter of at least 10%, as assessed by echocardiography. In receiver operating characteristic curve analysis, the optimum cut-off value for baseline galectin-3 with the highest Youden index was 59 ng/ml. RESULTS: Overall, LVRR at 12 months was observed in 38 patients (66%). In a univariate analysis, NYHA functional class and baseline galectin-3 levels were associated with LVRR. After adjustment for covariates, galectin-3 remained an independent predictor for LVRR. CONCLUSIONS: Our study suggests that baseline galectin-3 is an independent predictor of LVRR. Low levels of galectin-3 may be regarded a useful biomarker of favorable ventricular remodeling in patients with RODCM.
format Online
Article
Text
id pubmed-6029471
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-60294712018-07-17 Galectin-3 as a Predictor of Left Ventricular Reverse Remodeling in Recent-Onset Dilated Cardiomyopathy Karatolios, Konstantinos Chatzis, Georgios Holzendorf, Volker Störk, Stefan Richter, Anette Binas, Davis Schieffer, Bernhard Pankuweit, Sabine Dis Markers Research Article OBJECTIVES: Studies have evaluated the association of galectin-3 and outcome in patients with heart failure. However, there is still scarce evidence concerning the clinical usefulness and predictive value of galectin-3 for left ventricular reverse remodeling (LVRR) in patients with recent-onset dilated cardiomyopathy (RODCM). PATIENTS AND METHODS: Baseline galectin-3 was measured in 57 patients with RODCM. All patients were followed for at least 12 months. The study end point was LVRR at 12 months, defined as an absolute improvement of the left ventricular ejection fraction of ≥10% to a final value of ≥35%, accompanied by a decrease in the left ventricular end diastolic diameter of at least 10%, as assessed by echocardiography. In receiver operating characteristic curve analysis, the optimum cut-off value for baseline galectin-3 with the highest Youden index was 59 ng/ml. RESULTS: Overall, LVRR at 12 months was observed in 38 patients (66%). In a univariate analysis, NYHA functional class and baseline galectin-3 levels were associated with LVRR. After adjustment for covariates, galectin-3 remained an independent predictor for LVRR. CONCLUSIONS: Our study suggests that baseline galectin-3 is an independent predictor of LVRR. Low levels of galectin-3 may be regarded a useful biomarker of favorable ventricular remodeling in patients with RODCM. Hindawi 2018-06-19 /pmc/articles/PMC6029471/ /pubmed/30018673 http://dx.doi.org/10.1155/2018/2958219 Text en Copyright © 2018 Konstantinos Karatolios et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Karatolios, Konstantinos
Chatzis, Georgios
Holzendorf, Volker
Störk, Stefan
Richter, Anette
Binas, Davis
Schieffer, Bernhard
Pankuweit, Sabine
Galectin-3 as a Predictor of Left Ventricular Reverse Remodeling in Recent-Onset Dilated Cardiomyopathy
title Galectin-3 as a Predictor of Left Ventricular Reverse Remodeling in Recent-Onset Dilated Cardiomyopathy
title_full Galectin-3 as a Predictor of Left Ventricular Reverse Remodeling in Recent-Onset Dilated Cardiomyopathy
title_fullStr Galectin-3 as a Predictor of Left Ventricular Reverse Remodeling in Recent-Onset Dilated Cardiomyopathy
title_full_unstemmed Galectin-3 as a Predictor of Left Ventricular Reverse Remodeling in Recent-Onset Dilated Cardiomyopathy
title_short Galectin-3 as a Predictor of Left Ventricular Reverse Remodeling in Recent-Onset Dilated Cardiomyopathy
title_sort galectin-3 as a predictor of left ventricular reverse remodeling in recent-onset dilated cardiomyopathy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029471/
https://www.ncbi.nlm.nih.gov/pubmed/30018673
http://dx.doi.org/10.1155/2018/2958219
work_keys_str_mv AT karatolioskonstantinos galectin3asapredictorofleftventricularreverseremodelinginrecentonsetdilatedcardiomyopathy
AT chatzisgeorgios galectin3asapredictorofleftventricularreverseremodelinginrecentonsetdilatedcardiomyopathy
AT holzendorfvolker galectin3asapredictorofleftventricularreverseremodelinginrecentonsetdilatedcardiomyopathy
AT storkstefan galectin3asapredictorofleftventricularreverseremodelinginrecentonsetdilatedcardiomyopathy
AT richteranette galectin3asapredictorofleftventricularreverseremodelinginrecentonsetdilatedcardiomyopathy
AT binasdavis galectin3asapredictorofleftventricularreverseremodelinginrecentonsetdilatedcardiomyopathy
AT schiefferbernhard galectin3asapredictorofleftventricularreverseremodelinginrecentonsetdilatedcardiomyopathy
AT pankuweitsabine galectin3asapredictorofleftventricularreverseremodelinginrecentonsetdilatedcardiomyopathy